Niran Amar is a Rheumatology/Immunology physician affiliated with Allergy Asthma Research Institute. OpenAlex indexes 23 publications with 751 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Londonderry Dr
Ste 100
Waco, TX 767127930
Telephone
254-751-1144Provider last certified this registry record 27 Dec 2021.
Clinical trials
- Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
Sponsor: Alcon Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
51 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20255 payments
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- CSL BehringProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
88.4%Corticosteroid40.2%Fluticasone Propionate52%Trelegy Ellipta24%Symbicort8%Breo Ellipta5%Breztri Aerosphere4%Arnuity Ellipta3%Pulmicort Flexhaler2%Mometasone Furoate2%Part D<11 patientsHistamine-1 Receptor Antagonist19.4%Azelastine Hcl66%Levocetirizine Dihydrochloride22%Azelastine-Fluticasone12%Part D≥95 patients+ 3 more classes in this area
Anti-infectives
4.1%Macrolide Antimicrobial2.5%Azithromycin100%Part D≥37 patientsCephalosporin Antibacterial1.6%Cefdinir100%Part D≥24 patientsDermatology
3.9%Corticosteroid3%Triamcinolone Acetonide100%Part D≥29 patientsInterleukin-4 Receptor alpha Antagonist1%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis
Annals of Allergy Asthma & Immunology
2022 - Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis
Annals of Allergy Asthma & Immunology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”